<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245947</url>
  </required_header>
  <id_info>
    <org_study_id>3142A3-102</org_study_id>
    <nct_id>NCT00245947</nct_id>
  </id_info>
  <brief_title>Study Evaluating ERB-041 in Active Crohn's Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with
      inflammation associated with active Crohn's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory serum markers</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacogenomics</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Crohn's Disease Activity Index (CDAI) scores.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell surface markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal markers</measure>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Crohn's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERB-041</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, minimum 18 years of age with a diagnosis of Crohn's disease greater
             than 3 months,

          -  Eligible subjects must have adequate hematologic, renal, and hepatic function.

        Other inclusions apply

        Exclusion Criteria:

          -  Use of the following medications within the specified time period before randomization
             is prohibited:

        Within 48 hours before randomization

          -  Nonsteroidal antiinflammatory drugs (NSAIDs) Within 2 weeks before randomization

          -  Herbal supplements (except for a daily multivitamin/mineral supplement not containing
             herbal components).

        Other exclusions applies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2005</study_first_submitted>
  <study_first_submitted_qc>October 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2005</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <keyword>Crohn's Disease</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

